



**News from  
Integrated Sensing Systems Inc. (ISSYS)**

**FOR IMMEDIATE RELEASE**

Monday, January 13, 2003

Contact: Mike Ammann  
(734) 547-9896 Ext 105

**Integrated Sensing Systems (ISSYS) Receives 3 NASA Small  
Business Innovative Research (SBIR) Contracts**

Ypsilanti, MI -- Integrated Sensing Systems, Inc. (ISSYS) announced that the National Aeronautics and Space Administration (NASA) awarded them three Phase I, SBIR contracts. These projects will develop advanced, miniaturized, wireless, batteryless, pressure and flow implantable sensors, as well as create a new platform for incorporation of a variety of other sensors, for space studies.

The project titles and their associated web site addresses (for more detailed information) are listed below:

- ?? Implantable, space-worthy, batteryless biotelemetric monitor for animal studies  
[http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir\\_html/024213.html](http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir_html/024213.html)
- ?? Chronic Telemetric Biofluid Flow Monitoring Device  
[http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir\\_html/024213.html](http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir_html/024213.html)
- ?? A Wireless Communications Platform for Implantable Micro instruments  
[http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir\\_html/024217.html](http://sbir.gsfc.nasa.gov/SBIR/abstracts/02/sbir_html/024217.html)

Dr. Nader Najafi, ISSYS CEO, stated, "It's very gratifying to win these three contracts from such a competitive solicitation. NASA's support is critical to continue the development of ISSYS's cutting-edge, implantable, sensing technology, and extending its use into new application areas such as space research."

Michael Ammann, VP of Business Development for ISSYS, pointed out that key support from NASA SBIR program is essential for the future commercial development of ISSYS advanced core pressure

sensor technology since the small size of the company prevents an adequate investment in such a high-risk and early stage research.

The technology spillover of these three NASA-supported projects will include the monitoring and treatment of two major diseases: congestive heart failure (CHF) and hydrocephalus (elevated pressure of the brain). According to National Institute of Health (NIH), CHF is the new epidemic in U.S. that affects 4.7 million U.S. patients with more than 400,000 new cases diagnosed per year in U.S. Hydrocephalus has become the most common birth defects, now estimated at 1 per 1,000 births. Hydrocephalus can become a later stage onset in adult cases with approximately 70,000 patients discharged from hospitals with the diagnosis of hydrocephalus each year.

ISSYS is a world leader in developing chronic, wireless, batteryless, implantable sensors for the treatment of these two diseases. Initial animal studies for CHF were successfully performed in collaboration with the University of Michigan, and hydrocephalus animal implants will be performed this coming fall

Upon successful completion of each of these three Phase I NASA contracts, ISSYS will become eligible to compete for Phase II awards that allow for the next steps in a multi-step development of this technology towards providing a viable clinical tool for both medical and space applications

### **Company Background:**

ISSYS is a leader in advanced micromachining technologies for medical devices, microfluidic and analytical sensing applications used in the development of drug infusion pumps and wireless, implantable sensing systems. Founded in 1995 by world renowned leaders in MEMS technology, ISSYS operates an "everything under one roof" multi-million-dollar, state-of-the-art Bio-MEMS fabrication facilities located in Ypsilanti, MI.

For more company product and service information, please visit <http://www.mems-issys.com/> and <http://www.Nanogetters.com/> or Contact: Mike Ammann of Integrated Sensing Systems, Inc., (734) 547-9896 Ext. 105, or [ammann@mems-issys.com](mailto:ammann@mems-issys.com)

- end -